The Journal of Immunology, Vol 149, Issue 9 3003-3007, Copyright © 1992 by American Association of Immunologists

ARTICLES

Depletion of CD4+ T cells but not inhibition of the protective activity of IFN-gamma prevents cure of toxoplasmosis mediated by drug therapy in mice

FG Araujo
Research Institute, Palo Alto Medical Foundation, CA 94301.

Toxoplasmosis is a frequent opportunistic infection in patients with AIDS. In these patients the major immune deficiencies are a severe depletion of CD4+ T lymphocytes and an impaired capacity to produce IFN- gamma. A mouse model was developed and used to study the effects that depletion of CD4+ T cells and/or inhibition of the protective activity of IFN-gamma have on the effectiveness of the drug therapy for toxoplasmosis. Infection of mice with a lethal inoculum of Toxoplasma gondii cysts followed by treatment with the hydroxynaphthoquinone 566C80 or with sulfadiazine resulted in 100% survival whereas untreated controls had 100% mortality within 15 days of infection. Administration of antiserum to IFN-gamma resulted in early death of untreated mice and in 30% mortality in those treated. Administration of mAb to CD4+ T cells followed by infection with T. gondii prevented the development of both antibody and cell-mediated immune responses against the parasite. These mice resisted the acute infection while undergoing specific treatment. Discontinuation of the treatment, however, resulted in reactivation of the infection and the majority of the animals died within 17 days of suspension of the treatment. Administration of antiserum to IFN-gamma or to CD4+ T cells 24 h but not 15 days after conclusion of the treatment also resulted in mortality. These results indicate that successful treatment of toxoplasmosis depends on the status of the immune system, particularly of CD4+ T cells. Although it is speculative to compare results obtained in mice to the situation in humans, our work suggests that restoration of a competent immune response is of crucial importance for a successful treatment of toxoplasmosis in immunocompromised individuals.

This article has been cited by other articles:

				S. Lutjen, S. Soltek, S. Virna, M. Deckert, and D. Schluter Organ- and Disease-Stage-Specific Regulation of Toxoplasma gondii-Specific CD8-T-Cell Responses by CD4 T Cells. Infect. Immun., October 1, 2006; 74(10): 5790 - 5801. [Abstract] [Full Text] [PDF]

				E. S. Bernardes, N. M. Silva, L. P. Ruas, J. R. Mineo, A. M. Loyola, D. K. Hsu, F.-T. Liu, R. Chammas, and M. C. Roque-Barreira Toxoplasma gondii Infection Reveals a Novel Regulatory Role for Galectin-3 in the Interface of Innate and Adaptive Immunity Am. J. Pathol., June 1, 2006; 168(6): 1910 - 1920. [Abstract] [Full Text] [PDF]

				S. T. Smiley, P. A. Lanthier, K. N. Couper, F. M. Szaba, J. E. Boyson, W. Chen, and L. L. Johnson Exacerbated Susceptibility to Infection-Stimulated Immunopathology in CD1d-Deficient Mice J. Immunol., June 15, 2005; 174(12): 7904 - 7911. [Abstract] [Full Text] [PDF]

				L. L. Johnson and P. C. Sayles Deficient Humoral Responses Underlie Susceptibility to Toxoplasma gondii in CD4-Deficient Mice Infect. Immun., January 1, 2002; 70(1): 185 - 191. [Abstract] [Full Text] [PDF]

				G. Reichmann, E. N. Villegas, L. Craig, R. Peach, and C. A. Hunter The CD28/B7 Interaction Is Not Required for Resistance to Toxoplasma gondii in the Brain but Contributes to the Development of Immunopathology J. Immunol., September 15, 1999; 163(6): 3354 - 3362. [Abstract] [Full Text] [PDF]

				E. Y. Denkers and R. T. Gazzinelli Regulation and Function of T-Cell-Mediated Immunity during Toxoplasma gondii Infection Clin. Microbiol. Rev., October 1, 1998; 11(4): 569 - 588. [Abstract] [Full Text] [PDF]